- Home
- YALA vs ACRS Comparison
YALA vs ACRS Comparison
Compare YALA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | ACRS |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.7M | 868.5M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | YALA | ACRS |
|---|---|---|
| Price | $5.52 | $5.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 329.8K | ★ 1.8M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | $4.24 |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.01 | $1.74 |
| 52 Week High | $8.10 | $6.60 |
Technical Indicators
Market Signals| Indicator | YALA | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 50.42 |
| Support Level | $5.22 | $5.64 |
| Resistance Level | $5.67 | $6.56 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 63.64 | 33.34 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.